Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 study to evaluate preliminary anti-tumor activity, safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BDC-1001
administered as a single agent and in combination with pertuzumab in subjects with human
epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) previously
treated with trastuzumab deruxtecan (Enhertu®).